Summit Therapeutics (SMMT) Notes Payables (2021 - 2024)
Historic Notes Payables for Summit Therapeutics (SMMT) over the last 4 years, with Q3 2024 value amounting to $24.5 million.
- Summit Therapeutics' Notes Payables fell 7550.0% to $24.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $24.5 million, marking a year-over-year decrease of 7550.0%. This contributed to the annual value of $19.8 million for FY2022, which is N/A changed from last year.
- As of Q3 2024, Summit Therapeutics' Notes Payables stood at $24.5 million, which was down 7550.0% from $100.0 million recorded in Q2 2024.
- Summit Therapeutics' Notes Payables' 5-year high stood at $100.0 million during Q3 2023, with a 5-year trough of $19.8 million in Q4 2022.
- For the 4-year period, Summit Therapeutics' Notes Payables averaged around $59.8 million, with its median value being $55.0 million (2021).
- Within the past 5 years, the most significant YoY rise in Summit Therapeutics' Notes Payables was 7550.0% (2024), while the steepest drop was 7550.0% (2024).
- Over the past 4 years, Summit Therapeutics' Notes Payables (Quarter) stood at $55.0 million in 2021, then tumbled by 64.03% to $19.8 million in 2022, then surged by 405.82% to $100.0 million in 2023, then crashed by 75.5% to $24.5 million in 2024.
- Its last three reported values are $24.5 million in Q3 2024, $100.0 million for Q2 2024, and $100.0 million during Q3 2023.